Stock Analiz

Biogen Inc. (BIIB) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026

Summary

Biogen’s revenue went from $11.4B in fiscal 2016 to $9.9B in fiscal 2025, a decline of about 1.6% a year.

Net income in fiscal 2025 was $1.3B, a net margin of 13.1%; the best year in this period was 2019 with $5.9B.

Over the twelve months to September 30, 2026, revenue was $10.3B and net income $348M.

Free cash flow was $2.1B in fiscal 2025 and positive in 10 of the 10 years shown.

The diluted share count fell 33% over the period (buybacks).

Revenue, profit and cash flow by year

Revenue
2016: $11.4B162017: $12.3B172018: $13.5B182019: $14.4B192020: $13.4B202021: $11.0B212022: $10.2B222023: $9.8B232024: $9.7B242025: $9.9B25$9.9B
Net income
2016: $3.7B162017: $2.5B172018: $4.4B182019: $5.9B192020: $4.0B202021: $1.6B212022: $3.0B222023: $1.2B232024: $1.6B242025: $1.3B25$1.3B
Free cash flow
2016: $4.0B162017: $3.7B172018: $5.4B182019: $6.6B192020: $3.8B202021: $3.4B212022: $1.1B222023: $1.3B232024: $2.7B242025: $2.1B25$2.1B
EPS (diluted)
2016: $16.93162017: $11.92172018: $21.58182019: $31.42192020: $24.80202021: $10.40212022: $20.87222023: $7.97232024: $11.18242025: $8.7925$8.79

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$10.3B$9.9B$9.7B$9.8B$10.2B$11.0B$13.4B$14.4B$13.5B$12.3B$11.4B
Gross profit$7.6B$7.5B$7.4B$7.3B$7.9B$8.9B$11.6B$12.4B$11.6B$10.6B$10.0B
Operating income$750M$1.6B$1.9B$1.3B$3.6B$2.8B$4.6B$7.0B$5.9B$5.3B$5.2B
Net income$348M$1.3B$1.6B$1.2B$3.0B$1.6B$4.0B$5.9B$4.4B$2.5B$3.7B
EPS (diluted)$2.32$8.79$11.18$7.97$20.87$10.40$24.80$31.42$21.58$11.92$16.93
R&D$2.2B$1.8B$2.0B$2.4B$2.2B$2.5B$4.0B$2.3B$2.6B$2.3B$2.0B
Revenue growth—+2.2%−1.6%−3.3%−7.4%−18.3%−6.5%+6.9%+9.6%+7.2%+6.4%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$2.2B$2.2B$2.9B$1.5B$1.4B$3.6B$4.2B$7.1B$6.2B$4.6B$4.6B
Capital spending-$176M-$154M-$154M-$277M-$240M-$258M-$425M-$514M-$771M-$867M-$616M
Free cash flow$2.1B$2.1B$2.7B$1.3B$1.1B$3.4B$3.8B$6.6B$5.4B$3.7B$4.0B
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks——$0$0$750M$1.8B$6.7B$5.9B$4.4B$1.4B$1.0B
Stock-based pay$302M$291M$291M$264M$254M$239M$198M$182M$158M$128M$155M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$3.8B$2.4B$1.0B$4.9B$3.8B$2.6B$4.5B$1.2B$1.6B$2.3B
Debt—$6.7B$6.7B$7.4B$6.7B$9.0B$8.0B$8.0B$6.0B$5.9B$6.5B
Equity—$18.3B$16.7B$14.8B$13.4B$10.9B$10.7B$13.3B$13.0B$12.6B$12.1B
Total assets—$29.4B$28.0B$26.8B$24.6B$23.9B$24.6B$27.2B$25.3B$23.7B$22.9B
Shares (diluted)148M147M146M146M146M150M161M187M205M213M219M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin74.0%75.7%76.1%74.2%77.6%80.8%86.6%86.4%86.5%86.7%87.1%
Operating margin7.3%15.7%19.7%13.2%35.3%25.9%33.8%49.0%43.8%43.5%45.0%
Net margin3.4%13.1%16.9%11.8%29.9%14.2%29.8%41.0%32.9%20.7%32.3%
FCF margin20.1%20.7%28.1%12.9%11.2%30.8%28.3%45.6%40.3%30.0%34.7%
ROIC—5.2%7.0%5.2%14.7%13.9%19.6%27.7%23.4%15.0%20.7%
ROE—7.1%9.8%7.8%22.7%14.3%37.4%44.1%34.0%20.1%30.5%

Frequently asked questions

What is Biogen’s annual revenue?

$9.9B in fiscal 2025 and $10.3B over the twelve months to September 30, 2026.

How much profit does Biogen make?

Net income was $1.3B in fiscal 2025 (net margin 13.1%).

Is Biogen’s revenue growing?

Yes: revenue rose 2.2% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.